SGCB and Cirrhosis: Although this trial did not show reductions in markers of fibrosis, preclinical studies of sGC modulation in various models have shown that promoting sGC activity and, thus increasing cyclic guanosine monophosphate production, can both decrease portal pressure and exert antifibrotic effects.19–21,33,34 Phase II studies of BI 685509 in patients with cirrhosis have been designed and are ongoing to investigate the efficacy of BI 685509 to ameliorate PH (ie, to decrease HVPG).